The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 254-264

  Guan, Guofeng ^a   Zhang, Yinglong ^a   Lu, Yao ^a   Liu, Lijuan ^b   Shi, Doufei ^c   Wen, Yanhua ^a   Yang, Lianjia ^a   Ma, Qiong ^a   Liu, Tao ^a   Zhu, Xiaodong ^c   Qiu, Xiuchun ^a   Zhou, Yong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CXCR4; HIF 1 ; Hypoxia; Metastasis; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KC 7F2; PLERIXAFOR; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN; CXCR4 PROTEIN, MOUSE;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL MIGRATION; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOCHONDROMA; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR PROMOTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; CELL MOTION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; BONE NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOSARCOMA; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84920427515     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.034     Document Type: Article

References (55)

1. Jo V.Y., Fletcher C.D. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 2014, 46(2):95-104. pmid:24378391.
2. Hogendoorn P.C., Athanasou N., Bielack S., et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol 2010, 21(Suppl. 5):v204-v213. pmid:22997441.
3. Gordon N., Kleinerman E.S. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J. Aerosol Med. Pulm. Drug Deliv 2010, 23(4):189-196. pmid:20528149.
4. Buddingh E.P., Anninga J.K., Versteegh M., et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr. Blood Cancer 2010, 54(2):216-221. pmid:19890902.
5. Aksnes L.H., Hall K.S., Folleraas G., et al. Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience. Acta Oncol 2006, 45(1):38-46. pmid:16464794.
6. Bacci G., Longhi A., Versari M., et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006, 106(5):1154-1161. pmid:16421923.
7. Lewis I.J., Nooij M.A., Whelan J., et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J. Natl. Cancer Inst 2007, 99(2):112-128. pmid:17227995.
8. Bleul C.C., Farzan M., Choe H., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382(6594):829-833. PubMed: 8752280.
9. Wu B., Chien E.Y., Mol C.D., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330(6007):1066-1071. pmid:20929726.
10. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res 2010, 16(11):2927-2931. pmid:20484021.
11. Oda Y., Yamamoto H., Tamiya S., et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod. Pathol 2006, 19(5):738-745. pmid:16528367.
12. Philip B., Ito K., Moreno-Sanchez R., et al. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013, 34(8):1699-1707. pmid:23740838.
13. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst 2001, 93(4):266-276. pmid:11181773.
14. Hutchison G.J., Valentine H.R., Loncaster J.A., et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin. Cancer Res 2004, 10(24):8405-8412. pmid:15623619.
15. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol 2006, 70(5):1469-1480. pmid:16887934.
16. Nepal M., Choi H.J., Choi B.Y., et al. Anti-angiogenic and anti-tumor activity of bavachinin by targeting hypoxia-inducible factor-1alpha. Eur. J. Pharmacol 2012, 691(1-3):28-37. pmid:22760073.
17. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59(22):5830-5835. pmid:10582706.
18. Isobe T., Aoyagi K., Koufuji K., et al. Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1alpha) expression in gastric cancer. Int. J. Clin. Oncol 2013, 18(2):293-304. pmid:22350022.
19. Yang Q.C., Zeng B.F., Dong Y., et al. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn. J. Clin. Oncol 2007, 37(2):127-134. pmid:17237146.
20. Chen W.L., Feng H.J., Li H.G. Expression and significance of hypoxemia-inducible factor-1alpha in osteosarcoma of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod 2008, 106(2):254-257. pmid:18554951.
21. Guo M., Cai C., Zhao G., et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma. PLoS ONE 2014, 9(3):e90518. pmid:24618817.
22. Staller P., Sulitkova J., Lisztwan J., et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425(6955):307-311. pmid:13679920.
23. Ishikawa T., Nakashiro K., Klosek S.K., et al. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol. Rep 2009, 21(3):707-712. pmid:19212630.
24. Liu Y.L., Yu J.M., Song X.R., et al. Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol. Ther 2006, 5(10):1320-1326. pmid:16929169.
25. Cronin P.A., Wang J.H., Redmond H.P. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer 2010, 10:225. pmid:20492653.
26. Romain B., Hachet-Haas M., Rohr S., et al. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol. Cancer 2014, 13:58. pmid:24629239.
27. Hendrix C.W., Flexner C., MacFarland R.T., et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother 2000, 44(6):1667-1673. pmid:10817726.
28. Sarchio S.N., Scolyer R.A., Beaugie C., et al. Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer. J. Invest. Dermatol 2014, 134(4):1091-1100. pmid:24226205.
29. Zhu S., Hong J., Tripathi M.K., Sehdev V., Belkhiri A., El-Rifai W. Regulation of CXCR4-mediated invasion by DARPP-32 in gastric cancer cells. Mol. Cancer Res 2013, 11(1):86-94. pmid:23160836.
30. Cho K.S., Yoon S.J., Lee J.Y., et al. Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model. Oncol. Lett 2013, 6(4):933-938. pmid:24137439.
31. Sun X., Charbonneau C., Wei L., Yang W., Chen Q., Terek R.M. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis. Mol. Cancer Ther 2013, 12(7):1163-1170. pmid:23686836.
32. Berghuis D., Schilham M.W., Santos S.J., et al. The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease. Clin. Sarcoma Res 2012, 2(1):24. pmid:23249693.
33. Domanska U.M., Boer J.C., Timmer-Bosscha H., et al. CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. Clin. Exp. Metastasis 2014, 31(7):829-839. pmid:25154297.
34. Domanska U.M., Timmer-Bosscha H., Nagengast W.B., et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 2012, 14(8):709-718. pmid:22952424.
35. Narita T., Yin S., Gelin C.F., et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin. Cancer Res 2009, 15(19):6128-6136. pmid:19789328.
36. Koh M.Y., Spivak-Kroizman T.R., Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin. Cancer Res 2009, 15(19):5945-5946. pmid:19789327.
37. Damron T.A., Ward W.G., Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report. Clin. Orthop. Relat. Res 2007, 459:40-47. pmid:17414166.
38. Ma Q., Zhou Y., Ma B., et al. The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: a pilot study. Oncol. Lett 2012, 3(4):797-801. pmid:22740996.
39. Remmele W., Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8(3):138-140. pmid:3303008.
40. Chen X., Yang T.T., Wang W., et al. Establishment and characterization of human osteosarcoma cell lines with different pulmonary metastatic potentials. Cytotechnology 2009, 61(1-2):37-44. pmid:20016965.
41. Rapisarda A., Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol 2012, 9(7):378-390. pmid:22525710.
42. Legare M.E., Bush J., Ashley A.K., et al. Cellular and phenotypic characterization of canine osteosarcoma cell lines. J. Cancer 2011, 2:262-270. pmid:21552385.
43. Jin F., Brockmeier U., Otterbach F., et al. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol. Cancer Res 2012, 10(8):1021-1031. pmid:22767589.
44. Gilkes D.M., Semenza G.L. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 2013, 9(11):1623-1636. pmid:24156323.
45. Nys K., Maes H., Dudek A.M., et al. Uncovering the role of hypoxia inducible factor-1alpha in skin carcinogenesis. Biochim. Biophys. Acta 2011, 1816(1):1-12. pmid:21338656.
46. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 2004, 5:27. pmid:15341671.
47. Arlt M.J., Banke I.J., Walters D.K., et al. LacZ transgene expression in the subcutaneous Dunn/LM8 osteosarcoma mouse model allows for the identification of micrometastasis. J. Orthop. Res 2011, 29(6):938-946. pmid:21284029.
48. Wong I.H., Chan A.T., Johnson P.J. Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. Clin. Cancer Res 2000, 6(6):2183-2188. pmid:10873067.
49. Gacche R.N., Meshram R.J. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog. Biophys. Mol. Biol 2013, 113(2):333-354. pmid:24139944.
50. Mizobuchi H., Garcia-Castellano J.M., Philip S., et al. Hypoxia markers in human osteosarcoma: an exploratory study. Clin. Orthop. Relat. Res 2008, 466(9):2052-2059. pmid:18528739.
51. Yang Q.C., Zeng B.F., Shi Z.M., et al. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J. Exp. Clin. Cancer Res 2006, 25(4):593-599. pmid:17310851.
52. Salimath B., Marme D., Finkenzeller G. Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 2000, 19(31):3470-3476. pmid:10918605.
53. Adamski J., Price A., Dive C., et al. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. PLoS ONE 2013, 8(6). e65304. pmid:23785417.
54. Roncuzzi L., Pancotti F., Baldini N. Involvement of HIF-1alpha activation in the doxorubicin resistance of human osteosarcoma cells. Oncol. Rep 2014, 32(1):389-394. pmid:24840054.
55. Indovina P., Rainaldi G., Santini M.T. Hypoxia increases adhesion and spreading of MG-63 three-dimensional tumor spheroids. Anticancer Res 2008, 28(2A):1013-1022. pmid:18507049.